Other Publications

National Blood Authority Corporate Plan 2006-2009 (1.42MB)

HFA Conference Presentation - A national focus on patient needs (2.1MB)

International and National Intravenous Immunoglobulin Use (295KB)

Estimating Demand for Factor VIII up to 2015 - A Discussion Paper (217KB)

The Supply and Use of Plasma Products in Australia (700KB)

Australian Health Ministers Advisory Council (AHMAC) FVIII & FIX guidelines (2006) (1.26MB)

Australian Government 2008-09 Portfolio Budget Statements
Portfolio Agency Budget Statement (122KB)
Portfolio Agency Budget Statement (1.59MB)

The IVIg LITERATURE REVIEW (2004)
In 2003, on behalf of all Australia Governments the National Blood Authority (NBA) commissioned a Systematic Literature Review of IVIg Use and its Risks (2004). This document identifies and critically appraises the scientific literature surrounding the efficacy and risks of treatment with IVIg, including existing guidelines that identify the key therapeutic issues in IVIg therapy and dosing regimens. Importantly, the document includes studies comparing IVIg with other treatments, including immunoglobulin administered by other routes when studied in comparison with IVIg.

• Systematic Literature Review into the Efficacy of IVIg and its Risks (2004) (172KB)
• Appendix 2 - Summary Data on Conditions and Papers (2004) (872KB)
• Appendix 3 - Summary Data on IVIG Safety (2004) (64KB)
• Appendix 4 - Excluded References (2004) (56KB)

Guidelines on the prophylactic use of Rh D immunoglobulin (anti-D) in obstetrics - June 2003 (850KB)
This document, produced by the National Blood Authority and approved by the National Health and Medical Research Council, updates previous guidelines on the use of Rh D immunoglobulin (anti-D) released in 1999. It aims to inform clinicians, other health professionals and policy makers about the revised recommendations for use of anti-D in Australia.

Since the release of this document, the National Blood Authority has announced Stage 2 in a three-stage program, which extends routine antenatal prophylaxis to all Rh (D) negative women without preformed antibodies.

Further information on the use of anti-D during pregnancy is available from the Australian Red Cross Blood Service.

National Blood Authority Brochure (818KB)
This brochure outlines the roles, responsibilities and operational structure of the National Blood Authority.

Report of the Working Party on the Supply and Use of Factor VIII and Factor IX in Australia - April 2003 (547KB)
This report outlines the findings of a Working Party established in 1998 by the Blood and Blood Products Committee of the Australian Health Ministers' Advisory Council to review the use of the factor VIII and factor IX in Australia.

Report of the Expert Advisory Group on Hepatitis C and Plasma in 1990 - May 2003 (821KB)
This report examines claims that plasma testing positive to the Hepatitis C antibody was used in the manufacture of plasma products for several months in 1990, and recommends the establishment of the National Blood Authority in order to enhance the safety and security of Australia's blood supply.

Review of use and supply of intravenous immunoglobulin in Australia - June 2000 (262KB)
This report examines the demand for, and supply of, intravenous immunoglobulin (IVIG) across Australia, and was developed by a Working Party operating under the auspices of the Blood and Blood Products Committee of the Australian Health Ministers' Advisory Council.

Review of the alternatives to homologous blood donation - April 1999 (184KB)
This report re-evaluates the alternatives to homologous blood transfusion in Australia, and was developed by a Working Party operating under the auspices of the Blood and Blood Products Committee of the Australian Health Ministers' Advisory Council.